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Objective/Background: Tuberculosis (TB) infection is still a major public health burden in
Indonesia. TB cases in Indonesia constitute 35% of all the TB cases detected worldwide
and the prevalence of TB drug resistance in this country is approximately 3%. The aim of
this study was to evaluate the resistance of Mycobacterium tuberculosis to first-line TB drugs
among isolates from clinical specimens from a hospital in an urban area.
Methods: This laboratory-based study was conducted in Tangerang District, Indonesia,
from January 2011 to December 2014. Sputum and other clinical specimens were obtained
from patients with pulmonary and extrapulmonary TB. The specimens were stained with
Ziehl–Neelsen, inoculated on Lo¨wenstein–Jensen media for 6–8 weeks, and tested for sen-
sitivity against first-line TB drugs [isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and
streptomycin (SM)].
Results: All TB patients in this study lived in urban areas with male preponderance. Of
the 127 M. tuberculosis isolates collected, 22% showed resistance to first-line TB drugs.
Among these resistant isolates, 20.5% showed resistance to at least one of the first-line
TB drugs and 0.8% showed multidrug resistance (MDR). Resistance to EMB, INH, RIF,
and SM was seen in 6.3% 6.3%, 4.7%, and 1.6% of isolates, respectively. Polyresistance to
EMB and INH, EMB and RIF, and EMB, INH, and RIF was seen in 0.8% of the isolates,
respectively.
Conclusion: Our study confirms that drug resistance, including MDR, observed against all
first-line TB drugs was a real threat in the management of TB infection in Indonesia. The
resistance pattern identified in this study could assist clinicians in providing appropriate
treatment regimen to TB patients and improve their clinical outcome.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is a disease caused by acid-fast
bacilli Mycobacterium tuberculosis, which infects the lungs(pulmonary TB) and other organs (extrapulmonary) such as
the brain, spine, lymph nodes, abdomen, genitourinary
system, skin, and joints [1]. Drug-resistant-TB (DR-TB),
especially multidrug-resistant TB (MDR-TB) and extensiveBoulevard,
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in many countries. According to the 2014 World Health Orga-
nization Global Report, of the estimated 9 million TB cases in
the world, approximately 56% were from South-East Asia and
Western Pacific regions. Of these TB cases, 3.5% of new cases
and 20.5% of retreatment cases were attributed to MDR-TB [2].
Indonesia is one of the countries with the highest TB preva-
lence, with 430,000 new TB cases reported every year, and
an estimated MDR-TB proportion of 1.9% among new cases
and 12% among retreatment cases [2]. The directly observed
treatment, short course (DOTS) strategy implemented since
1995 by the Indonesian National TB Program (NTP) has
enabled Indonesia to reach the global target for new smear-
positive TB case notification rate—73 cases/100,000 popula-
tion in 2010 [3]. Routine monitoring of DR-TB is very impor-
tant because of the limited availability of first-line TB drugs,
the high price of second-line TB drugs, and lack of facilities
in most health-care centers in Indonesia that could detect
DR-TB or have access to second-line TB treatment [4]. There-
fore, data on local TB drugs resistance are essential for
patient management and selection of appropriate regimen
for patients suspected to have the resistance strain, as this
helps to prevent the spread of resistant TB [2,5]. Thus, the
aim of this study was to evaluate the resistance of M. tubercu-
losis to first-line TB drugs among isolates from clinical speci-
mens from a hospital in an urban area of Indonesia
(Tangerang District).
Materials and methods
This study was conducted in Siloam General Hospital, Tanger-
ang District, Indonesia. Tangerang is a city in Banten Pro-
vince, located approximately 25 km from Jakarta. The study
area is one of the largest cities in Indonesia with a population
of approximately 2 million distributed over an area of 164.55
km2. The Disease Control, Prevention and Health Environ-
ment Bureau reported that in 2012, Banten Province had
286.7 new TB cases/100,000 population, and the crude death
rate in this region was 1.1% [6]. Patients in the participating
hospital represented a wide range of socioeconomic strata.
Epidemiological data of TB patients and microbiological
data of M. tuberculosis from various clinical specimens and
its resistance to first-line TB drugs were retrospectively col-
lected from January 2011 to December 2014. Sputum was col-
lected early morning on 3 consecutive days. Other specimens
were collected from bronchial fluid, cerebrospinal fluid, urine,
and pus from abscess. The diagnosis of pulmonary and extra-
pulmonary TB was made by clinicians based on history, phys-
ical examination, chest radiography, and positive acid-fast
bacilli smear, and/or culture [7,8].
Drug-susceptibility testing
All specimens underwent decontamination and homogeniza-
tion using sodiumhydroxide at a final concentration of 2% fol-
lowed by Ziehl–Neelsen staining [9,10]. The drug-susceptibility
testingagainst first-lineTBdrugswas carriedoutusing thepro-
portional method after inoculating the specimens on Lo¨wen-
stein–Jensen (LJ) medium and incubating them at 37 C. TheLJ medium was observed two times a week, for 6–8 weeks, to
check for growth of the pathogen. The growth was compared
with the international standard strain of M. tuberculosis
H37Rv, which is used to detect resistance [10,11]. The drug sus-
ceptibility was determined as the percentage of colonies that
grew on the following concentration of four first-line TB drugs:
isoniazid (INH), 0.1 lg/mL, 1 lg/mL, and 10 lg/mL; rifampicin
(RIF), 2.5 lg/mL, 5 lg/mL, and 20 lg/mL; ethambutol (EMB),
1 lg/mL, 10 lg/mL, and 100 lg/mL; and streptomycin (SM),
1 lg/mL, 10 lg/mL, 100 lg/mL, respectively [10].
Definition
Any drug resistance was defined as resistance to one or more
first-line TB drugs (INH, RIF, EMB, and SM). Monoresistance
was defined as resistance to only one first-line TB drug, and
polyresistance was defined as resistance to at least two or
more first-line TB drugs except the INH and RIF combination
[8,12]. MDR-TB was defined as resistance to the two key
first-line TB drugs, namely, INH and RIF [2,5].
Results
The total number of positive culture forM. tuberculosiswas 127
(15, 37, 45, and 30 cultures collected consecutively in 2011,
2012, 2013, and 2014, respectively). All patients in this study
lived in urban areas (55.1% male and 44.9% female patients).
Other profiles of TB patients are presented in Table 1.
The proportion of resistance to first-line TB drugs during
4-year observation period is presented in Table 2. Most of
the M. tuberculosis isolates were collected from sputum spec-
imens (87.4%). Isolates collected from the cerebrospinal fluid
of patients with brain infection caused by M. tuberculosis con-
stituted 2.4% of the total specimen. The highest prevalence of
any drug resistance was noted in 2012 and 2014. Twenty eight
(22%) of the 127M. tuberculosis isolates collected showed resis-
tance; among these, 24 (18.9%) were monoresistant and two
(1.6%) were polyresistant. There was only one isolate of
MDR-TB, which was found in 2014. The overall resistance to
single drugs was noted in eight isolates (6.8%; against EMB
and INH); six (94.7%) isolates were resistant to RIF and two
isolates (1.6%) were resistant to SM. Polyresistance to EMB
and INH and EMB and RIF was noted in 0.8% of the isolates,
respectively (n = 1 each).
Discussion
In last decades, Indonesia has been identified as one of the
countries with the highest TB prevalence in the world. The
incidence of TB has decreased as reported by the NTP report.
However, the emergence and spread of DR-TB threatens TB
control and has become a major public health problem in
Indonesia. Development of DR-TB, including MDR, is attribu-
ted to poor patients’ compliance, inappropriate TB drug regi-
men, inadequate laboratory facilities for drug-susceptibility
testing, and acceleration of human immunodeficiency virus
epidemic [3,5,13,14].
In this study, 18.9% ofM. tuberculosis isolates were resistant
to at least one first-line TB drug. This number was lower than
Table 2 – Resistance pattern of Mycobacterium tuberculosis to first-line TB drugs from 2011 to 2014.
TB drug-resistance patterna Year Total cases
2011 2012 2013 2014
n = 15, n (%) n = 37, n (%) n = 45, n (%) n = 30, n (%) n = 127, n (%)
Susceptibility 14 (93.3) 27 (73.0) 35 (77.8) 23 (76.7) 106 (83.5)
Any drug resistanceb 1 (6.7) 10 (27.0) 10 (22.2) 7 (23.3) 28 (22.0)
INH 1 (6.7) 3 (8.1) 3 (6.7) 2 (6.7) 9 (7.1)
RIF 0 (0.0) 2 (5.4) 2 (4.4) 3 (10.0) 7 (5.5)
EMB 0 (0.0) 4 (10.8) 4 (8.9) 2 (6.7) 10 (7.9)
SM 0 (0.0) 1 (2.7) 1 (2.2) 0 (0.0) 2 (1.6)
Monoresistancec 1 (6.7) 10 (27.0) 6 (13.3) 7 (23.3) 24 (18.9)
INH 1 (6.7) 3 (8.1) 2 (4.4) 2 (6.7) 8 (6.3)
RIF 0 (0.0) 2 (5.4) 1 (2.2) 3 (10.0) 6 (4.7)
EMB 0 (0.0) 4 (10.8) 2 (4.4) 2 (6.7) 8 (6.3)
SM 0 (0.0) 1 (2.7) 1 (2.2) 0 (0.0) 2 (1.6)
Polyresistanced 0 (0.0) 0 (0.0) 2 (4.4) 0 (0.0) 2 (1.6)
RIF + EMB 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (0.8)
INH + EMB 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (0.8)
MDRe 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3) 1 (0.8)
EMB = ethambutol; INH = isoniazid; MDR = multidrug resistance; RIF = rifampicin; SM = streptomycin.
a Local data in a hospital.
b Any drug resistance: resistance to any of the first-line TB drugs.
c Monoresistance: resistance to only one first-line TB drug.
d Polyresistance: resistance to at least two or more first-line TB drugs except INH and RIF combination.
e MDR: resistance to at least INH and RIF.
Table 1 – Epidemiological and clinical profile of tuberculosis patients.
Year Total cases
2011 2012 2013 2014 n = 127, n (%)
Female 7 12 21 17 57 (44.9)
Male 8 25 24 13 70 (55.1)
Type of specimen
Bronchial fluid 2 2 1 3 8 (6.3)
Sputum 11 33 42 25 111 (87.4)
Cerebrospinal fluid 1 1 1 0 3 (2.4)
Pus 1 0 1 2 4 (3.1)
Urine 0 1 0 0 1 (0.8)
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[15] in Makassar, Indonesia, where the proportion of
M. tuberculosis resistant to at least one first-line TB drug
reached 40% in new and retreatment cases. The proportion
of DR in this study was also lower than that reported Nana
et al. [16] in China where 33.3% isolates were resistant to all
first-line TB drugs. The resistance to TB drugs in this study
was comparable with other studies in Asia where the propor-
tion of resistance ranged from 18.7% to 30.2% [16,17].
The proportion of resistance to INH and EMB was 6.3%,
which was similar to a previous study in Iran, where propor-
tion of resistance to INH was 8% and EMB was 5.5% [18]. Most
of the previous studies in South-East Asia andWestern Pacific
regions showed that the resistance level to INH was higher
with a range of 10.2–37% [18,19,20]. Resistance to INH in this
study might be due to poor management or the INH resis-
tance prior to the current treatment [17,18]. Previous studies
conducted by Ayaz et al. [7] and Sasmono et al. [21] reportedthat the proportion of INH resistance was not associated with
ethnicity, but only with socioeconomic strata or limited
health-care facilities. The proportion of INH resistance
exceeding 10% predicts the development of MDR-TB [17,22].
Therefore, M. tuberculosis culture with drug-susceptibility
testing for at least INH and RIF should be performed for all
TB patients before the start of treatment [2,20]. A meta-
analysis by van der Werf and Langendam [23] reported that
patients who took inappropriate TB drugs regimen and
patients who had treatment failure were on a 27-fold risk of
getting MDR-TB. The low proportion of MDR-TB in 2014 in this
study was similar to the result from other studies [7,17,20].
This result indicates that the Stop TB program with DOTS
and the use of local-specific drug-resistance data are effective
in preventing the spread of MDR-TB.
Our study population mainly included patients attending a
private general hospital; in addition, our sample size was
small, and therefore, this may not be a representative of all
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ulation is needed to determine the level of MDR, design a
standard empirical MDR regimen, and monitor the spread of
MDR-TB. The recommendation of appropriate treatment reg-
imen will also improve successful treatment and survival [24].
Conclusion
Our study confirms that DR, including MDR, observed against
all first-line TB drugs was a real threat in the management of
TB infection. The resistance pattern in this study could assist
the clinicians in providing appropriate treatment regimen to
TB patients and improve their clinical outcome.
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